Trial Investigates Combined Empagliflozin and Liraglutide for Heart Failure in Diabetes
Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial
Background
Patients with Type 2 Diabetes Mellitus often face an increased risk of developing congestive heart failure (CHF), a serious condition where the heart cannot pump enough blood effectively. Existing treatments like SGLT2 inhibitors (e.g., empagliflozin) and GLP-1 receptor agonists (e.g., liraglutide) have shown individual benefits for both diabetes and cardiovascular outcomes. However, there's a significant knowledge gap regarding the specific mechanistic insights and potential synergistic effects of combining these two drug classes in managing CHF in diabetic patients.
Study Design
Population
Patients with Type 2 Diabetes Mellitus and congestive heart failure.
Intervention
Combined empagliflozin and liraglutide.
Outcome
Specific mechanistic insights and potential synergistic effects of combining empagliflozin and liraglutide in managing CHF in diabetic patients.
TitrateLab articles covering Liraglutide
Written by TitrateLab, separately from the study summarized above.
